The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2020 | Novel approaches to CLL treatment
Arnon Kater, MD, PhD, University of Amsterdam, Amsterdam, Netherlands, discusses novel approaches to chronic lymphocytic leukemia (CLL) treatment, including the use of single-agent targeted therapies such as venetoclax and ibrutinib over chemotherapy as well as T-cell based therapies for consolidation therapy. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
